NASDAQ:CDTX

Cidara Therapeutics Stock Forecast, Price & News

$2.56

+0.05 (+1.99 %)

(As of 01/25/2021 03:52 PM ET)

Add

Compare

Today's Range

$2.46

Now: $2.56▼

$2.58

50-Day Range

$2.00

MA: $2.19▼

$2.46

52-Week Range

$1.30

Now: $2.56▼

$4.45

Volume31,746 shs

Average Volume421,872 shs

Market Capitalization$112.48 million

P/E RatioN/A

Dividend YieldN/A

Beta1.66

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

MarketRank^™

Overall MarketRank^™

1.89 out of 5 stars

Medical Sector

96th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

7th out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.75, Cidara Therapeutics has a forecasted upside of 164.7% from its current price of $2.55.
Amount of Analyst Coverage
Cidara Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Cidara Therapeutics has received 390 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cidara Therapeutics has received 297 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cidara Therapeutics has received 56.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote “Outperform” if you believe CDTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cidara Therapeutics does not currently pay a dividend.
Dividend Growth
Cidara Therapeutics does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.75% of the stock of Cidara Therapeutics is held by insiders.
Percentage Held by Institutions
60.06% of the stock of Cidara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Cidara Therapeutics are expected to grow in the coming year, from ($1.44) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cidara Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cidara Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cidara Therapeutics has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CDTX

Previous Symbol

CUSIPN/A

CIK1610618

Webwww.cidara.com

Phone858-752-6170

Employees68

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio1.78

Quick Ratio1.78

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$20.92 million

Price / Sales5.38

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.15 per share

Price / Book2.23

Profitability

EPS (Most Recent Fiscal Year)($1.41)

Net Income$-41,090,000.00

Net Margins-662.48%

Return on Equity-165.58%

Return on Assets-92.73%

Miscellaneous

Outstanding Shares43,938,000

Market Cap$112.48 million

Next Earnings Date3/3/2021 (Estimated)

OptionableOptionable

$2.56

+0.05 (+1.99 %)

(As of 01/25/2021 03:52 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

How has Cidara Therapeutics' stock price been impacted by COVID-19?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDTX stock has increased by 3.2% and is now trading at $2.56.
View which stocks have been most impacted by COVID-19.

Is Cidara Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cidara Therapeutics stock.
View analyst ratings for Cidara Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cidara Therapeutics?

Wall Street analysts have given Cidara Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cidara Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Cidara Therapeutics.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.01. The biotechnology company had revenue of $2.42 million for the quarter, compared to analyst estimates of $3.56 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 165.58% and a negative net margin of 662.48%.
View Cidara Therapeutics' earnings history.

What price target have analysts set for CDTX?

4 analysts have issued 1-year price targets for Cidara Therapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Cidara Therapeutics' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 163.7% from the stock's current price.
View analysts' price targets for Cidara Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Cidara Therapeutics' key competitors?

Some companies that are related to Cidara Therapeutics include CASI Pharmaceuticals (CASI), Lineage Cell Therapeutics (LCTX), Aptose Biosciences (APTO), Solid Biosciences (SLDB), Cardiff Oncology (CRDF), Innate Pharma (IPHYF), Cellular Biomedicine Group (CBMG), Innate Pharma (IPHA), Ocugen (OCGN), Eiger BioPharmaceuticals (EIGR), Cabaletta Bio (CABA), Voyager Therapeutics (VYGR), Checkmate Pharmaceuticals (CMPI), LogicBio Therapeutics (LOGC) and PDL BioPharma (PDLI).
View all of CDTX's competitors.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:

Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 66, Pay $797.1k)
Mr. Neil Abdollahian M.B.A., M.S., Chief Bus. Officer (Age 48, Pay $550.1k)
Dr. Taylor Sandison, Chief Medical Officer (Age 49, Pay $568.3k)
Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 44)
Mr. James E. Levine, Chief Financial Officer (Age 50)
Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 52)
Mr. Brady Johnson, Principal Accounting Officer, Controller & Director of Fin.
Mr. Christopher A. Kurtz, Exec. VP of Technical Operations (Age 54)
Ms. Jessica Oien J.D., Gen. Counsel & Sec. (Age 50)
Dr. Kenneth F. Bartizal Ph.D., Chief Devel. Officer (Age 70)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $2.56.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $112.48 million and generates $20.92 million in revenue each year. The biotechnology company earns $-41,090,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is www.cidara.com.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here